MedTrace Logo

Exercise Therapy for Isotretinoin Users

NCT07196787 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-12-02

No results posted yet for this study

Summary

Isotretinoin (13-cis retinoic acid) is a retinoic acid that is a derivative of vitamin A. Isotretinoin has been used effectively alone in acne treatment for 35 years. However, it has many side effects. Among the musculoskeletal side effects of this treatment, acute sacroileitis is a common condition. In this clinical picture, recovery may last for a few months after discontinuation of isotretinoin treatment. However, it may become permanent in some cases. According to our current knowledge, there is no study in the literature that prescribes exercise therapy for this patient group. This study, planned to investigate the effects of stretching and sacroiliac mobilization exercises on musculoskeletal pain and quality of life, which are among the side effects of isotretinoin treatment.

Conditions

  • Isotretinoin
  • Isotretinoin Adverse Reaction

Interventions

OTHER

Exercise

The 18-Week Program Structure This program is divided into three 6-week phases. Each week consists of 5 sessions, mixing different focuses to ensure balanced development. Day 1: Foundational Strength \& Stability Day 2: Low-Impact Cardio \& Active Recovery Day 3: Core Focus \& Hip Stability Day 4: Low-Impact Cardio \& Mobility Day 5: Full Body Integration \& Strength

Sponsors & Collaborators

  • Uşak University

    lead OTHER

Principal Investigators

  • Ali Y Karahan, MD · Uşak University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-02-06
Completion
2026-03-26

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07196787 on ClinicalTrials.gov